Saturday, December 17, 2016
Trials for Joshie (and Paulster and others....if needed)....
I've made links to trials first with a brief description below each ~
A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors
This one does note brain mets in past 2 years as well as immunotherapy as a "partial" exclusion. So I am not quite sure what that means. Is recruiting in Chicago.
Safety, Tolerability, Pharmacokinetic/Pharmacodynamic and Preliminary Efficacy Study of BMS-986205 Administered in Combination With Nivolumab in Advanced Cancers
This one has the exclusion of if you have taken nivo in a trial with the end point of overall survival. But, if nivo was not from that sort of trial....it seems to be okay. I think BMS-986205 in an oral IDO inhibitor. Info on it alone is a little hard to find. Also recruiting in Chicago, I think.
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
"This is a first-in-human, first-in-class, escalating dose trial of an antibody that inhibits an anti-apoptotic signal in human macrophages." There don't seem to be any exclusions that would be a problem. It is active in San Antonio and California...and is supposed to be recruiting soon in Michigan.
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma
This is the dynavax with pembro trial and is recruiting in California, Colorado, NC, Penn, Tx, and Utah. Some arms do have an exclusion for prior immunotherapy...but it looks as though some allow it. Here's a link about it: Onclive conference
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
This one is recruiting in Maryland, NY, Penn, and Tx. You have be off any steroids for a couple of weeks...but there doesn't seem to be any other exclusion that would affect you. However, you do have to be positive for B7H3, a surface antigen, that they will test your tumor for. It is good to know that something like more than 94% of melanomas ARE positive for this antigen.
Safety Study of MGA271 in Refractory Cancer
This one is enoblitzumab alone. Recruiting in Cal, Chicago, Mass, NC, Penn, and Nashville. There seem to be NO problematic exclusions. Still need to be positive for B7H3. Here's an article about enoblitzumab: https://jitc.biomedcentral.com/articles/10.1186/2051-1426-3-S2-P177
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
No problematic exclusions, I don't think. Not sure this is really worth much when you need a response in a hurry, since both vaccines and immunotherapy take time...but - Recruiting in Virginia, Cleveland, Ohio, NC and Atlanta.
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
This was first mentioned by Brian on MPIP. It is pretty cool. They analyze your tumor to see what "other" drug...usually used in other cancers....might be effective on yours. They are doing it in a couple places in Chicago and a zillion places across the US. Sometimes melanoma that is unresponsive to typical drugs WILL respond to those usually used in breast cancer and others because of its genetic makeup.
Then there are a variety of intralesionals combined with immunotherapy....T-VEC, PV-10, etc.
Not sure how much this helps. Hang in there dear Josh and Paul. Thanks to all the ratties. And for all of you - Hug your dear ones...and enjoy every moment. - love, c
P.S. Remembered this one overnight!!!
Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma
There do not seem to be any exclusion obstacles. It is recruiting at Stanford, Moffitt, John Hopkins, in Boston, Chicago, NYU, Penn, Tx and even France, Germany and Spain!!! Even better, I happen to know of 2 melanoma patients who had been progressing in dire ways despite every treatment in the book who are currently at Yale (I think), undergoing this therapy and for the first time are better or at least no longer progressing. Here's some additional info...albeit from the company!